NEW TAIPEI CITY, May 11, 2024
/PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to
announce its participation to share the latest clinical
advancements at the upcoming 2024 BIO International Convention on
Wednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place
in Company Presentation Theater 2 at the San Diego Convention Center.
The annual BIO International Convention, hosted by Biotechnology
Innovation Organization (BIO), stands as the world's premier
industry event, convening over 20,000 esteemed biotechnology and
pharmaceutical leaders from around 5,000 reputable companies. The
four-day, in-person event includes latest topic forums, networking
and partnering opportunities. Caliway is one of the 200+ companies
poised to present at this event.
Caliway anticipates this opportunity to share recent progress on
its lead pipeline candidate, CBL-514, with the international
biotechnology and pharmaceutical community. CBL-514's Phase 2
studies have demonstrated efficacy in multiple indications. For
reducing subcutaneous fat, an average of 312.1 mL was achieved. It
also showed promise for treating Dercum's disease as well as
cellulite. These findings mark a significant step forward in
providing effective solutions for these medical conditions.
About Caliway Biopharmaceuticals
Caliway Biopharmaceuticals (Caliway) is a Taiwan-headquartered, clinical-stage
biopharmaceutical company driven by the discovery of breakthrough
small-molecule therapeutics with a focus on medical aesthetics and
inflammatory disease.
Listed on the emerging stock market in Taiwan (TPEX6919), Caliway aims to become an
innovative pharmaceutical leader in aesthetic medicine. For more
information, please visit: http://www.Caliway.com.tw/en
Disclaimer
This article and related information on this site contain
forward-looking statements. The forward-looking information
requires the Company to make numerous assumptions and is subject to
inherent risks, uncertainties, and other factors that are beyond
the control of the Company which may cause actual results,
performance or achievements to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. The Company undertakes no obligation to
timely inform, update, or revise the information on this site if
circumstances should change.
For additional contact: info@caliway.com.tw
View original content to download
multimedia:https://www.prnewswire.com/news-releases/caliway-to-present-the-latest-clinical-advancements-at-2024-bio-international-convention-302142897.html
SOURCE Caliway Biopharmaceuticals